| Literature DB >> 29437771 |
Prabhjot S Bedi1, Manoj P Rai2, Nishant Tageja3, Heather Laird-Fick4.
Abstract
An 82-year-old Caucasian woman with a history of basal cell carcinoma on vismodegib presented with nausea, vomiting and intermittent abdominal pain. Laboratory results were remarkable for the elevation of liver enzymes. Endoscopic retrograde cholangiopancreatography and percutaneous transhepatic cholangiogram (PTC) did not show evidence of intrahepatic or extrahepatic obstruction of the biliary tract. During PTC external biliary catheter was placed; however, bilirubin continued to rise. Further, laboratory work-up and imaging studies ruled out other possible aetiologies for hepatotoxicity such as infections, autoimmune hepatitis and other drugs known to be hepatotoxic thus leaving vismodegib the most likely cause of hepatotoxicity. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.Entities:
Keywords: liver disease; oncology; unwanted effects / adverse reactions
Mesh:
Substances:
Year: 2018 PMID: 29437771 PMCID: PMC5836615 DOI: 10.1136/bcr-2017-222969
Source DB: PubMed Journal: BMJ Case Rep ISSN: 1757-790X